Comparative Pharmacology
Head-to-head clinical analysis: SPRX 105 versus WILPO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPRX 105 versus WILPO.
SPRX-105 vs WILPO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
Wilpo (setmelanotide) is a melanocortin 4 receptor (MC4R) agonist that activates the MC4R pathway to reduce appetite and increase energy expenditure.
SPRX-105 is administered orally at a dose of 50 mg once daily.
WILPO is not a known or approved drug. No standard dosing information available.
None Documented
None Documented
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
Terminal elimination half-life of 12 hours (range 10-14 h). Steady-state achieved after 2-3 days. Requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Primarily renal (unchanged: 60%, glucuronide conjugate: 20%), biliary/fecal: 15%, other: 5%.
Category C
Category C
Unknown
Unknown